GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption

被引：0
|
作者：
Bakkour, Waseem [1 ]
Coulson, Ian H. [1 ]
机构：
[1] Burnley Gen Hosp, Dept Dermatol, Burnley, Lancs, England
来源：
DERMATOLOGY AND THERAPY | 2012年 / 2卷 / 01期
关键词：
Anti-CD20 monoclonal antibody; GA101; Lichenoid drug eruption; Rituximab;
D O I：
10.1007/s13555-012-0003-9
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Introduction: Obinutuzumab (GA101) is a novel anti-CD20 monoclonal antibody that has been shown to be effective for the treatment of non-Hodgkin's lymphoma, and is currently being evaluated in phase 3 clinical trials. The side-effect profile of the drug is not yet well established. Case report: The authors report a case of a 62-year-old patient who developed widespread lichenoid eruption as a result of GA101 treatment for his follicular non-Hodgkin's lymphoma. Conclusion: This is the first case report of cutaneous side effects of GA101.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption
    Waseem Bakkour
    Ian H. Coulson
    [J]. Dermatology and Therapy, 2012, 2 (1)
  • [2] Obinutuzumab (GA101) - a different anti-CD20 antibody with great expectations
    Illidge, Tim M.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (05) : 543 - 545
  • [3] IN VITRO ANALYSIS OF NOVEL ANTI-CD20 ANTIBODY GA101 AND RITUXIMAB IN MANTLE CELL LYMPHOMA
    Heinrich, D.
    Decheva, K.
    Weinkauf, M.
    Hutter, G.
    Zimmermann, Y.
    Weiglein, T.
    Hiddemann, W.
    Dreyling, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 70 - 70
  • [4] Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
    Dalle, Stephane
    Reslan, Lina
    de Horts, Timothee Besseyre
    Herveau, Stephanie
    Herting, Frank
    Plesa, Adriana
    Friess, Thomas
    Umana, Pablo
    Klein, Christian
    Dumontet, Charles
    [J]. MOLECULAR CANCER THERAPEUTICS, 2011, 10 (01) : 178 - 185
  • [5] A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
    Kensei Tobinai
    Christian Klein
    Naoko Oya
    Günter Fingerle-Rowson
    [J]. Advances in Therapy, 2017, 34 : 324 - 356
  • [6] A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
    Tobinai, Kensei
    Klein, Christian
    Oya, Naoko
    Fingerle-Rowson, Gunter
    [J]. ADVANCES IN THERAPY, 2017, 34 (02) : 324 - 356
  • [7] Ga101 is the most effective anti-CD20 mAb in ABC and GCB DLBCL and is antagonized by Ofatumumab via decrease of Ga101 induced apoptosis
    Zoellner, A. -K
    Weber, A.
    Zimmermann, Y.
    Hutter, G.
    Hiddemann, W.
    Dreyling, M.
    [J]. ONKOLOGIE, 2012, 35 : 39 - 40
  • [8] Ofatumumab: a novel monoclonal anti-CD20 antibody
    Lin, Thomas S.
    [J]. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2010, 3 : 51 - 59
  • [9] Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101
    Chien, Wei Wen
    Niogret, Charlene
    Juge, Romain
    Lionnard, Loic
    Cornut-Thibaut, Aurelie
    Kucharczak, Jerome
    Savina, Ariel
    Salles, Gilles
    Aouacheria, Abdel
    [J]. LEUKEMIA RESEARCH, 2017, 55 : 41 - 48
  • [10] Anti-CD20 Antibody GA101 Shows Higher Cytotoxicity but Is Competitively Displaced by Rituximab in Mantle Cell Lymphoma.
    Heinrich, Daniel A.
    Klein, Christian
    Decheva, Kristina
    Weinkauf, Marc
    Hutter, Grit
    Zimmermann, Yvonne
    Weiglein, Tobias
    Hiddemann, Wolfgang
    Dreyling, Martin H.
    [J]. BLOOD, 2009, 114 (22) : 1059 - 1059
12345